Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drugging RAS: Know the enemy
Bjoern Papke, Channing J. Der
Science (2017) Vol. 355, Iss. 6330, pp. 1158-1163
Open Access | Times Cited: 352

Showing 1-25 of 352 citing articles:

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1127
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Andrew M. Waters, Channing J. Der
Cold Spring Harbor Perspectives in Medicine (2017) Vol. 8, Iss. 9, pp. a031435-a031435
Open Access | Times Cited: 733
Overcoming Endocrine Resistance in Breast Cancer
Ariella B. Hanker, Dhivya R. Sudhan, Carlos L. Arteaga
Cancer Cell (2020) Vol. 37, Iss. 4, pp. 496-513
Open Access | Times Cited: 647
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant, Clint A. Stalnecker, Daniel Zeitouni, et al.
Nature Medicine (2019) Vol. 25, Iss. 4, pp. 628-640
Open Access | Times Cited: 574
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Zhenyi An, Ozlem Aksoy, Tina Zheng, et al.
Oncogene (2018) Vol. 37, Iss. 12, pp. 1561-1575
Open Access | Times Cited: 507
Integrative Proteomic Characterization of Human Lung Adenocarcinoma
Jun‐Yu Xu, Chunchao Zhang, Xiang Wang, et al.
Cell (2020) Vol. 182, Iss. 1, pp. 245-261.e17
Open Access | Times Cited: 454
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Jay B. Fell, John P. Fischer, Brian R. Baer, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 13, pp. 6679-6693
Open Access | Times Cited: 447
Acquired Resistance to KRASG12C Inhibition in Cancer
Mark M. Awad, Shengwu Liu, Igor I. Rybkin, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 25, pp. 2382-2393
Open Access | Times Cited: 439
Reactive Oxygen Species and Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and Cancer Progression
Jan Ježek, Katrina F. Cooper, Randy Strich
Antioxidants (2018) Vol. 7, Iss. 1, pp. 13-13
Open Access | Times Cited: 431
Targeted Protein Degradation: from Chemical Biology to Drug Discovery
Philipp M. Cromm, Craig M. Crews
Cell chemical biology (2017) Vol. 24, Iss. 9, pp. 1181-1190
Open Access | Times Cited: 351
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Andrew J. Aguirre, Jonathan A. Nowak, Nicholas D. Camarda, et al.
Cancer Discovery (2018) Vol. 8, Iss. 9, pp. 1096-1111
Open Access | Times Cited: 322
Targeting the untargetable KRAS in cancer therapy
Pingyu Liu, Yijun Wang, Xin Li
Acta Pharmaceutica Sinica B (2019) Vol. 9, Iss. 5, pp. 871-879
Open Access | Times Cited: 305
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Gongmin Zhu, Lijiao Pei, Hongwei Xia, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 281
Biomarker-guided therapy for colorectal cancer: strength in complexity
Anita Sveen, Scott Kopetz, Ragnhild A. Lothe
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 1, pp. 11-32
Open Access | Times Cited: 270
The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
Chengming Liu, Sufei Zheng, Runsen Jin, et al.
Cancer Letters (2019) Vol. 470, pp. 95-105
Open Access | Times Cited: 241
The Concise Guide to PHARMACOLOGY 2023/24: Enzymes
S P H Alexander, Doriano Fabbro, Eamonn Kelly, et al.
British Journal of Pharmacology (2023) Vol. 180, Iss. S2
Open Access | Times Cited: 235
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Dong-Sung Kim, Jenny Y. Xue, Piro Lito
Cell (2020) Vol. 183, Iss. 4, pp. 850-859
Open Access | Times Cited: 174
Precision oncology in metastatic colorectal cancer — from biology to medicine
Federica Di Nicolantonio, Pietro Paolo Vitiello, Silvia Marsoni, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 8, pp. 506-525
Open Access | Times Cited: 174
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
G. Aaron Hobbs, Nicole M. Baker, Anne M. Miermont, et al.
Cancer Discovery (2019) Vol. 10, Iss. 1, pp. 104-123
Open Access | Times Cited: 173
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Manuela Porru, Luca Pompili, Carla Caruso, et al.
Journal of Experimental & Clinical Cancer Research (2018) Vol. 37, Iss. 1
Open Access | Times Cited: 162
Emerging strategies to target RAS signaling in human cancer therapy
Kun Chen, Yalei Zhang, Ling Qian, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 160
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 151
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 134
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Albert K. Kwan, Gary A. Piazza, Adam B. Keeton, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 131
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 128
Page 1 - Next Page

Scroll to top